Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China-US Tensions Rise Sharply On Pelosi Visit, Will Biotech Get Burned?

Economic Countermeasures Already Taken

Executive Summary

Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.

You may also be interested in...



Chinese-Language Podcast: 聊聊七月生物制药热门话题

Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector. 

Taiwan 'A Great Place’ For Clinical Trials, But Tweaks Needed

Amid simmering regional geopolitical tensions, speakers at a recent conference highlighted the multiple benefits of conducting clinical trials in Taiwan, while pointing to what more could be done to improve the local ecosystem.

China Turns To New Vaccines As It Eases 'COVID Zero' Restrictions

In a significant policy shift and following recent public unrest, China now appears to be moving away from its strict "COVID Zero" restrictions to salvage a floundering economy hard hit by repeated lockdowns, as part of which it is looking to accelerate the approval of new vaccines and increase vaccination rates in the elderly.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel